Zentalis Pharmaceuticals Climbs in Debut After Expanded IPO

Bookmark
(Bloomberg) -- Zentalis Pharmaceuticals Inc., a clinical-stage cancer treatment developer, rose 29% in its trading debut after raising about $165 million in an initial public offering.
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.